Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01402986 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Tralokinumab in Adults With Asthma
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 689
- Enrollment target
NCT01402986 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 689 participants.
The verdict
NCT01402986, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 689 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the addition of tralokinumab to standard asthma medication is effective in the treatment of adults with asthma.
Interventions
- OTHER Placebo Q2W
- BIOLOGICAL Tralokinumab 300 mg, Q2W
- OTHER Placebo, Q2/4W
- BIOLOGICAL Tralokinumab 300 mg, Q2/4W
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 689 participants |
| Start Date | 2011-08 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01402986
The ClinicalTrials.gov registry entry for NCT01402986 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 689 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo Q2W is the first listed.
NCT01402986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01402986 about?
NCT01402986 is a clinical study titled "A Safety and Efficacy Study of Tralokinumab in Adults With Asthma". The purpose of this study is to determine whether the addition of tralokinumab to standard asthma medication is effective in the treatment of adults with asthma.
What is the current status of trial NCT01402986?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 689 participants. The study started on 2011-08. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01402986?
The interventions under investigation include: Placebo Q2W (OTHER), Tralokinumab 300 mg, Q2W (BIOLOGICAL), Placebo, Q2/4W (OTHER), Tralokinumab 300 mg, Q2/4W (BIOLOGICAL).
Who is sponsoring clinical trial NCT01402986?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.